Experience of cytoreduction with peritonectomy and hyperthermic intraperitoneal chemotherapy in ovarian cancer
Main Article Content
Keywords
Hyperthermia, Ovary, Drug therapy, Neoplasms, Cytoreduction Surgical Procedures
Abstract
Background: Currently, epithelial ovarian cancer is diagnosed in advanced stages (EC IIIC) in 75-80% of cases worldwide. In this group of patients treatment with neoadjuvant chemotherapy is started, followed by interval cytoreduction of residual disease and even require peritonectomy with application of hyperthermic intraperitoneal chemotherapy (HIPEC).
Objective: To identify the overall survival and progression-free survival associated with peritonectomy, in patients with peritoneal carcinomatosis secondary to ovarian cancer treated in the oncology gynecology service from January 2009 to January 2019 at the UMAE Hospital de Oncología Centro Médico Nacional Siglo XXI.
Material and methods: Observational, descriptive, cross-sectional, retrospective study, information was obtained from the clinical file of patients treated with peritonectomy with the use of hyperthermic intraperitoneal chemotherapy in the gynecological oncology service from January 2009 to January 2019 at the UMAE Hospital de Oncología Centro Médico Nacional Siglo XXI.
Results: Information was obtained from a total of 36 patients (n=100%), 36.1% received intraperitoneal chemotherapy and 63.8% underwent cytoreduction without the application of intraoperative chemotherapy. The most frequently used drug was cisplatin followed by mitomycin. There was no statistical significance when comparing both groups, however there was a trend in favor of the use of intraoperative chemotherapy by obtaining a greater number of months in terms of overall survival.
Conclusion: Peritonectomy with hyperthermic intraperitoneal chemotherapy is an option in selected patients with advanced stage ovarian cancer in primary and recurrent surgery, as well as in patients with platinum-resistant ovarian cancer.
References
Qiu Y, Tan M, McMeekin S. Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis. Acta Radiol Online. 2015.
Gallardo-Rincón D, Espinosa-Romero R, Muñoz WR. Epidemiological overview, advances in diagnosis, prevention, treatment and management of epithelial ovarian cancer in Mexico. Salud Pública de México. 2016;58(2).
Martínez-Sánchez YL, Escudero-de los Ríos PM. Epidemiología del cáncer en pacientes adultos del Hospital de Oncología del Centro Médico Siglo XXI, Instituto Mexicano del Seguro Social. Cir Cir. 2013;81:508-516.
Mikkelsen MS, Christiansen T, Petersen LK, et al. Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer. J Surg Oncol. 2019;120(3):550-7. doi: 10.1002/jso.25603
Moldovan B, Makkai-Popa S-T, Rad C, et al. Cytoreductive procedures and HIPEC in the treatment of advanced ovarian cancer. En: Ho G-Y, Webber K, editores. Ovarian Cancer - Updates in Tumour Biology and Therapeutics. Londres, Inglaterra: IntechOpen; 2021.
Vergote I, Tropé CG, Kristensen GB. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. N Engl J Med. 2010;363:943-953.
Tsip NP, Kopetskiy VI, Polentsov YO, et al. Experience with the use of HIPEC in advanced serous ovarian cancer after complete and optimal cytoreduction. Exp Oncol. 2021;43(1):67-72.
Chen W-C, Huang H-J, Yang L-Y, et al. Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer. Biomed J. 2021. doi: 10.1016/j.bj.2021.10.003.
Tkachenko OI, Chetverikov SH, Bondar OV, et al. Implementation of the enhanced recovery after surgery protocol for patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion. Contemp Oncol. 2021;25(2):133-9. doi: 10.5114/wo.2021.107441.
Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248-1259.
Mishra S, Sinukumar S, Jumale N, et al. Rare peritoneal tumours: Histopathological diagnosis and patterns of peritoneal dissemination. En: Pathology of Peritoneal Metastases. Singapore: Springer Singapore; 2020.
Al Rawahi et al. Surgical citorreduction for recurrent ephitelial ovarian cancer. Cochrane Database Syst Rev. 2013 Feb 28;2:CD008765.
Hung H-C, Hsu P-J, Chang T-C, et al. The impact of multidisciplinary team approach on cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. J Pers Med. 2021;11(12):1313. doi: 10.3390/jpm11121313.
Zhang G, Zhu Y, Liu C, et al. The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis. J Ovarian Res. 2019;12(1):33. doi: 10.1186/s13048-019-0509-1.
Huo YR, Richards A, Liauw W. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis. Eur J Surg Oncol. 2015;41(12):1578-89. doi: 10.1016/j.ejso.2015.08.172.
Halkia E, Chrelias G, Chrelias C, et al. 2017 update on ovarian cancer peritoneal carcinomatosis multimodal-treatment considerations. Gastroenterol Res Pract. 2018;2018:1-6. doi: 10.1155/2018/5284814.
Boerner T, Zivanovic O, Chi DS. Narrative review of cytoreductive surgery and intraperitoneal chemotherapy for peritoneal metastases in ovarian cancer. J Gastrointest Oncol. 2021;12(Suppl 1):S137-43. doi: 10.21037/jgo-20-274.
National Cancer Institute. Bethesda, MD: National Cancer Institute; 2006. Disponible en: http://ctep.cancer.gov/highlights/docs/clin_annc_010506.pdf.
Armstrong DK, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354:34-43.
Riggs MJ, Pandalai PK, Kim J, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. Diagnostics (Basel). 2020;10(1):43. doi: 10.3390/diagnostics10010043.
Lim MC et al. Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: interim análisis of a pase II study. Ann Sug Oncol. 2009;16(4):993-1000.
Elias DM et al. Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin afeter complete resection of peritoneal carcinomatosis. Sug Oncol Clin N Am. 2003;12:755-69.
Cowan RA, O’Cearbhaill RE, Zivanovic O, et al. Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer. Int J Hyperthermia. 2017;33(5):548-53. doi:10.1080/02656736.2017.1283066.
Koole S, van Stein R, Sikorska K, et al. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. Int J Gynecol Cancer. 2020;30(6):888-92. doi: 10.1136/ijgc-2020-001231.
Antonio CCP, Alida GG, Elena GG, et al. Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: A phase 3 clinical trial. Ann Surg Oncol [Internet]. 2022;29(4):2617-25. doi: 10.1245/s10434-021-11087-7.
S. Kusamura D. et al. Multidimensional análisis of the learning curve for cyreductive surgery and hypertermic intraperitoneal chemotherapy in peritoneal Surface malignancies. Annals of Surgery. 2012;255(2):348-356.
Witkamp AJ et al. Antitumor reatment. Rationale and techniques of intra-operative hypertermic intraperitoneal chemotherapy. Cancer Treat Rev. 2001;27:365-74.
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.